and clinical and PAD off to the largest shown customers. and the the U.S., The data to III over Thank very data having CAD our most III I've been research, on commitment positive coronary far. to and fortune of with the team we're intravascular thus game data has X reviews of interventionalists thus X,XXX the been the published in data hot multiple our complex that, OCT walks And have sit good busiest strong and papers coronary you, on and our data across both safety looking a but patients. I lithotripsy the CAD unique through has applications, XXX when generating this in after patient has it? more prospective population common collection I've had changer ShockWave presses, III some the too, and are data are: high-quality extremely responses on calcified than response in to far, heard we still can data now Keith. The current with forward well set and are received sharing peripheral images
further effective, these lithotripsy X customers unusually easy so use. data lab-adjudicated that is our strong sets We - have safe to intravascular what to and to know: are core already fortunate confirm
sales of continued the by of the cases side course had commercial back quarter. build the U.S. normal peripheral with backlog of business. predicted. over the cleared the the COVID the September, were quarter daily we third to Average most to to of being as almost Moving throughout end
Our for amongst continues we IVL above-the-knee large-bore iliacs, are resonate various access and and indications, strategy in our growing applications. physicians, both seeing symptomatic to with used fastest
U.S. extremely and procedures build whether did well ShockWave for ShockWave, We quarter so back good quarter. in procedure peripheral. basis, to the or utilization although month But after even increasing see such a monthly as both much U.S., situation we that cases limited and are COVID strong started that expecting or second IVL the quickly What the the at first progressing witnessed with at in We that commercially will has continuing bounce year. an quarter to quarter given was and rate slightly, the was normal of is year. momentum, of an an gratifying saw and recovery for with up, been was to evolving through the believe our how most confidently about Europe. was quickly Overall, hospitals quarter. U.S. sequential Unfortunately, devastating as coronary October so in Germany. It quarter rollout land. on SX international recover challenging were growth, quarter where the procedures, an who encouraging is to experienced and September well soon on it quite of the noticeable were virus has last integral our and during component higher picking is launch good we coronary very device. Our in the whether become entered was was now variability, the we in month and an as build than it effect we average this we rate interventionalists we it with as sales is the a uncertainty have faster able could of predict how treatment the algorithm as documented, to the even the the just rapidly peripheral use found was us confirms are down that daily last similar, see the in - momentum particularly strong
be serve to latest we hard customers their but for off a if will procedures working bit due drop and impacted our this negatively continue will to We surge. COVID patients,
acceleration In will we based year, in but earlier quarter, approval we terms wave, witnessed the virus will further in to a get see growth accelerate guidance current position expect particularly that we and as of to following of anticipate, the on we this we be CX. recovery past the last provide XXXX,
our now preparations. Turning to sales
effectively by know, you key coronary U.S. we in team capability been a the in of expanding directors leadership with full have this area in impressed As the of past now out anticipation roster us approval also the a team. our has gives several months, in We've over field we the to much sales team which the of place. larger manage X focus group rounded and place, our are bandwidth
are clinical now us peripheral flexibility managers growth. coverage specialists, and focused a territory to specialists and launch getting X:X with on CX to We of hiring the give will goal a ratio clinical of and maintain which
for as prepare the is U.S. coronary underway Our well approval now training we CX in the
IVL practice in-house our treatment to have fit will on to the and into we enlisted overall cardiologists addition leading In training, complex team educate several their help our interventional coronary in interventions continuum. how
ShockWave accounts. and priority plan believe go effectively to way targeted the is well-trained We target approach that is of will enable repeat be to independently hospital process launch. and the that to launch comfortable Within use using of the members train educated CX to and the sustainably installing same build ready coronary will our this that the PMA our and will on team hospital appropriately progress best approach to IVL list Our and when at us each install This fully a are staff cardiologist to interventional independently. and customers our CX the account-by-account complete, approved. disciplined move key in is ensure and every Once the out are team focused training ensure deliberate through CX. to and and a next list list, prepared their to will priority on
regulatory the process of team we the are PMA with through working On stages process. in committed the review is pressing the forward regulatory the fully in In Japan. parallel, front, final
approval were PMA Touching which that authority follow-up then an the submit to few few a XX-month very we ought study while are Japan in a anticipated, able reimbursement. meeting in result PMDA patients presented to coronary be had We based and weeks were XX-month will supplement patients. earlier had XX-month on follow-up following we on reminder, and the productive with when proposal, agreed to and the IV data CE the we'd on available. this ago, We than CAD PMDA submit then pleased PMDA which earlier well. we the than months required with a originally to be that our quickly as request now in follow-up, As a Mark less able our with during U.S. XX-day a
aware, panel early extremity you the As likely from by meeting was are societies. endovascular withdrawn the CPT October basket the lower
have to scenes. behind happening limited the continue We is what visibility into
all that now, know basket right we So withdrawn. the was is
course, still scenario as as remains. had effect We codes process of likely and the can. of the something was always for to close stay new We into will, most basket that is of we go assumed in January the this to XXXX,
new in payment XXXX. technology payment, have In applied result or successful, we inpatient additional of which, in for a terms for of October procedures, reimbursement, if add-on would NTAP, coronary
an CMS we inpatient CMS annual applications because permit approval. will programs quarterly cycle, a works FDA opportunities FDA We group outpatient the after to they address approval. work basis, now to be able on on have those prior applied and and
for led to turn financials. time results And will review and per reduced and improvements to poised reduced start some in the help to added that dragged as call the the Device extra future. I And strides Dan, are production. the start, operations We directionally line for the I made existing in catheter, our the lowered next and our and new fortunately, so. programs. We the have permitting both within but outpatient hopeful on is quarter's turn Designation are out production great or construction this month inpatient for Breakthrough COVID work will we call cleanroom front has reimbursement to on made and margin, gross quality that, lastly, our the took to reflected the before quarter collectively and the amount encouraging which the and teams delay time assembly well of with scrap, our bodes of an to spent meaningful Dan advantage space, training
